|Day Low/High||8.76 / 9.70|
|52 Wk Low/High||7.33 / 21.03|
Investors eyeing a purchase of Zogenix Inc. stock, but cautious about paying the going market price of $8.98/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Company will host a conference call today at 4:30 p.m. EDT/1:30 p.m. PDT
Podium Presentation to Highlight Efficacy, Cardiovascular Safety, Sleep Quality, and Quality of Life in Patients Receiving Low-Dose Fenfluramine for the Treatment of Dravet Syndrome
The most recent short interest data was recently released by the NASDAQ for the 03/01/2016 settlement date, and Zogenix Inc. is one of the most shorted stocks of the Russell 3000, based on 18.11 "days to cover" versus the median component at 5.60.
Trade-Ideas LLC identified Zogenix (ZGNX) as a weak on high relative volume candidate
Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST
Investors considering a purchase of Zogenix Inc. shares, but cautious about paying the going market price of $10.25/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Stocks with insider trader activity include SCVL, ZGNX and FRME
Stocks with insider trader activity include RNST, AMPH and ZGNX
New Clinical Data Presented at 69th Annual American Epilepsy Society Meeting on the Use of Low-Dose Fenfluramine in Managing Seizures Associated With Dravet Syndrome
Company Will Host a Conference Call Today at 4:30 p.m. EST/1:30 p.m. PST
Company Continues to Expect Phase 3 Clinical Program to Begin in Fourth Quarter of 2015
These stocks look ready to break out and trade higher from current levels.